Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03297996 · ClinicalTrials.gov registry record
Study of Gut Microbiome and Colorectal Tumors
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 540
- Enrollment target
NCT03297996: Completed study, sponsored by NYU Langone Health.
NCT03297996 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 540 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03297996 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 540 participants
- Enrollment target
Study Summary
Gut microbiota were assessed in 540 colonoscopy-screened adults by 16S rRNA gene sequencing of stool samples. Investigators compared gut microbiota diversity, overall composition, and normalized taxon abundance among these groups.
Primary Outcome
Quantitative polymerase chain reaction
Interventions
- DIAGNOSTIC_TEST Mobio PowerSoil DNA Isolation Kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2011-11-23 |
| Est. Completion | 2015-04-25 |
What the finished NCT03297996 record still lists
NCT03297996 is an observational study that tracks outcomes without assigning an intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Mobio PowerSoil DNA Isolation Kit is the first listed.
NCT03297996 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03297996 about?
NCT03297996 is a clinical study titled "Study of Gut Microbiome and Colorectal Tumors". Gut microbiota were assessed in 540 colonoscopy-screened adults by 16S rRNA gene sequencing of stool samples. Investigators compared gut microbiota diversity, overall composition, and normalized taxon abundance among these groups.
What is the current status of trial NCT03297996?
This trial is currently completed. The enrollment target is 540 participants. The study started on 2011-11-23. Estimated completion is 2015-04-25.
What interventions are being tested in trial NCT03297996?
The interventions under investigation include: Mobio PowerSoil DNA Isolation Kit (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03297996?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI